Icotinib, also known as BPI-2009, is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, is upregulated in a variety of cancer cell types.
EGFR Inhibitors Related Products:
Erlotinib; Erlotinib hcl; Gefitinib; AG-490; Dacomitinib; WZ4002; Pelitinib; Brigatinib analog; Allitinib; Rociletinib; Varlitinib; WHI-P154; CNX-2006; AG-18; Nazartinib